Meet the innovators merging biology and machine learning for better health
Trusted by























Next-Gen RNAseq: Speed, Savings, and AI-Enhanced Bioinformatics
featuresAI That Transforms Data into Discovery
AI-Powered RNA Insights at Your Fingertips
Pre-Aligned Read Counts
RNAseq at $80 for 10M reads, Process twice the samples without ballooning your budget.

OmicsWeb AI
Fast, Trusted Results, Complete gene counts + FASTQ delivered in under 2 week

BIRT Technology
Tiny Sample, Big Data, Only 10 ng RNA needed; accepts mixed tissue types.

Pre-Processed Data
Full‑Spectrum Coverage, Profiles mRNA and non‑coding RNA in one run.

AI automates bioinformatics today, then maps disease paths and treatment tomorrow

AI Tools for you
OmicsWeb Data Lake
Ingest, standardize, and compliance-secure omics data – AI ready immediately
QuantaQuill
Gen-AI writes papers and reports with beautiful figures and accurate citations—first drafts in a click
Bioinformatics Co-Pilot
Chat-run pipelines give every research an expert bioinformatician—no code needed
Embedding Surfer
Zoom through omics embeddings; uncover relationships invisible to conventional plots
Biostate.AI's customer support has been outstanding—they were responsive, knowledgeable, and made the entire process hassle-free. Their BIRT technology is also incredibly cost-effective, providing high-quality RNA-seq results without breaking the budget. What really stood out was the integration with OmicsWeb Copilot—it made data analysis so much easier. Instead of spending weeks manually processing and interpreting results, I was able to dive deep into the data with just a few clicks. OmicsWeb Copilot provided clear insights, helped identify key patterns, and ultimately saved me a lot of time and resources. It’s a game-changer for RNA-seq analysis!"
Working with Biostate.AI has been a great experience. The entire process—from data delivery to analysis—has been seamless. Having pre-aligned read counts made it incredibly easy to get started, and OmicsWeb Copilot has been a game-changer in our analysis. It helps dive deeper into the data, saving us a significant amount of time and resources. We’re excited about the insights we’re uncovering and look forward to future collaborations!”
"Partnering with BioState.AI has been a game-changer for our research. Their platform is not only incredibly powerful but also intuitive and adaptable to the unique needs of our projects. What truly sets them apart is their commitment to scientific rigor paired with cutting-edge machine learning—helping us accelerate discovery without compromising on quality or insight. The team is responsive, deeply knowledgeable, and genuinely invested in our success. With BioState AI, we’re not just accessing tools—we’re gaining a strategic partner in innovation.”
Biostate.AI's customer support has been outstanding—they were responsive, knowledgeable, and made the entire process hassle-free. Their BIRT technology is also incredibly cost-effective, providing high-quality RNA-seq results without breaking the budget. What really stood out was the integration with OmicsWeb Copilot—it made data analysis so much easier. Instead of spending weeks manually processing and interpreting results, I was able to dive deep into the data with just a few clicks. OmicsWeb Copilot provided clear insights, helped identify key patterns, and ultimately saved me a lot of time and resources. It’s a game-changer for RNA-seq analysis!"
Working with Biostate.AI has been a great experience. The entire process—from data delivery to analysis—has been seamless. Having pre-aligned read counts made it incredibly easy to get started, and OmicsWeb Copilot has been a game-changer in our analysis. It helps dive deeper into the data, saving us a significant amount of time and resources. We’re excited about the insights we’re uncovering and look forward to future collaborations!”
"Partnering with BioState.AI has been a game-changer for our research. Their platform is not only incredibly powerful but also intuitive and adaptable to the unique needs of our projects. What truly sets them apart is their commitment to scientific rigor paired with cutting-edge machine learning—helping us accelerate discovery without compromising on quality or insight. The team is responsive, deeply knowledgeable, and genuinely invested in our success. With BioState AI, we’re not just accessing tools—we’re gaining a strategic partner in innovation.”
Biostate.AI's customer support has been outstanding—they were responsive, knowledgeable, and made the entire process hassle-free. Their BIRT technology is also incredibly cost-effective, providing high-quality RNA-seq results without breaking the budget. What really stood out was the integration with OmicsWeb Copilot—it made data analysis so much easier. Instead of spending weeks manually processing and interpreting results, I was able to dive deep into the data with just a few clicks. OmicsWeb Copilot provided clear insights, helped identify key patterns, and ultimately saved me a lot of time and resources. It’s a game-changer for RNA-seq analysis!"
TestimonialsWhat Our Customers and Partners Say
CareerJoin us at the frontier of biology

FAQ
Right now, the treatment you receive as a patient is based on a “standard of care” that physicians and the medical establishment have determined is the most appropriate path for an average person. The problem is, none of us is an average person. In the case of complex diseases like cancer or autoimmune disease, every one of us responds to treatment differently. In a few cases, physicians can group people by age, gender, and even genetic background to deliver a little more tailored care, but they can’t predict, in most cases, which individuals will really respond well to the latest cancer treatments. Biostate’s long term vision is to create therapeutics that are customized to specific individuals, by using modern AI tools to integrate and analyze multiple kinds of complex medical data, from DNA genomes to small molecule metabolomes.
In fact, we’re called “Biostate.AI” because if you were to capture data from all the DNA, RNA, proteins, and small molecules in your blood, you’d have a pretty accurate picture of the state of your biology and could, with the help of AI, determine exactly the right custom treatment regimen for you. Acquiring and analyzing all the relevant molecules in your body to create personalized therapies is a huge vision, and we have to start somewhere a little more manageable. Instead of measuring everything, we’re focusing on measuring RNA transcriptomes, and instead of new custom drugs we’re focusing on diagnostics that will determine the best treatment path for individuals using existing treatments. We’re focusing on a few key diseases including leukemia, coronary artery disease, and multiple sclerosis and will create and sell medical tests to help doctors make better treatment decisions.
Our goals are still ambitious, and for AI to perform its magic we need to collect and organize massive amounts of RNA sequence data from thousands of patients. To accomplish this we’re establishing partnerships with doctors, health care systems and governments around the world to acquire samples and understand the most useful questions our AI can ask about these samples. RNA sequencing is expensive, and most companies have to pay “street price” for their data points—too much to afford the data that AI needs. At Biostate, we’ve developed our own proprietary RNA sequencing technologies that make RNA sequencing an order of magnitude less expensive. This allows us to affordably sequence the RNA samples we need to validate our own medical tests. And because our mission is to accelerate personalized medicine as much as possible, we are extending our RNA sequence pricing, as well as our AI software platform and services, to the broader medical and scientific research community.
Unlike companies that focus on just one part of the process, we’ve built an integrated system that handles everything from sample processing to AI analysis and insight generation. We achieve this integration by adopting AI, automation, and novel chemistry that leverage all of these elements together. BIRT and PERD are our biochemistry innovations that reduce RNA sequencing costs by 50-70% compared to traditional methods. OmicsWeb, Copilot, and QuantaQuill are our AI tools that transform how researchers analyze and interpret data. Our lab has also embraced automation to accelerate our workflows and increase throughput. This vertical integration creates efficiencies and insights that fragmented approaches simply can’t match.
We’re addressing three fundamental challenges in healthcare and biotech: (a) reducing the cost of omics technologies, starting with RNAseq but with more innovations coming soon, to enable data collection at unprecedented scale; (b) implementing AI in every aspect of biotech to massively accelerate research pace and insight generation; and (c) developing clinical insights drawing inspiration from how LLMs were developed. Traditional RNA sequencing is expensive (around $350 per sample), forcing researchers to limit their studies and preventing the collection of the massive datasets needed for effective AI. Additionally, the data requires specialized expertise to analyze, creating bottlenecks in research. We’ve solved these problems by drastically reducing costs, standardizing data collection to eliminate technical variation, and developing AI tools that allow non-experts to analyze complex data through natural language queries—essentially democratizing access to powerful biological insights.
Our technology benefits diverse groups across the healthcare and research ecosystem:
Academic Research Labs: Successfully sequence difficult samples like degraded FFPE tissue at 50-70% lower cost while enabling non-computational scientists to conduct sophisticated analyses without specialized expertise.
Pharmaceutical R&D: Deliver consistent, high-quality RNA-seq data across large cohorts for biomarker discovery while applying our pre-trained models to stratify patients for clinical trials.
Biobanks and Clinical Research Organizations: Enhance value of stored tissue collections through cost-effective sequencing while eliminating batch effects in multi-site studies.
Clinical Oncology Research: Capture disease dynamics missed by DNA-only approaches and develop models for treatment response and relapse risk beyond traditional markers.
Biotechnology Startups: Stretch limited research budgets by providing 3-5x more transcriptomic data for the same cost while eliminating the need for specialized bioinformatics staff.
Ultimately, patients benefit as these advances lead to more personalized and effective healthcare approaches.
We train our AI similar to how large language models like GPT are trained. First, we pre-train on massive amounts of unlabeled RNA data, allowing the AI to learn the “grammar” of biology—patterns related to age, sex, pathway activity, and disease states. Then we fine-tune for specific applications with much smaller labeled datasets. In some of our internal studies, this approach improved prediction accuracy from 65% with traditional machine learning to 89% with our method. This two-stage approach means we can build powerful models with much less labeled data than traditionally required, which is particularly valuable for developing diagnostics for rare conditions and situations where samples are difficult to obtain.
OmicsWeb Copilot is our AI assistant that allows researchers to analyze complex RNA data using simple, natural language questions instead of complex code. For example, you could ask “Which genes are overexpressed in my treatment group compared to control?” and Copilot will perform the appropriate statistical analysis and visualization. This eliminates the need to wait for specialized bioinformaticians, who are in short supply, and democratizes access to sophisticated analysis for scientists of all backgrounds. Combined with our QuantaQuill tool, which helps draft scientific reports and manuscripts, we’re dramatically accelerating the research cycle.
OmicsWeb is our comprehensive data lake that allows researchers to securely store their omics data in the cloud. It provides automated data analysis capabilities, seamless integration with Copilot for custom analyses, and tools to safely prepare and transform data. Researchers can easily consolidate their data with other datasets or public repositories to create robust training datasets. In the future, we plan to enable direct model training within OmicsWeb itself, creating a complete environment for omics data management, analysis, and AI development—all without requiring specialized computational infrastructure or expertise.
We’re building what we call the “Netflix for molecular medicine” through a multi-phase approach. We begin with revolutionary RNA sequencing services that generate immediate revenue while building our data assets. Next, we’ll develop clinical tests that predict disease outcomes and treatment responses. Ultimately, we aim to enable truly personalized “N-of-1” therapeutics tailored to individual molecular profiles, transforming healthcare from reactive to predictive and from one-size-fits-all to truly personalized medicine. Each phase funds and de-risks the next, creating a sustainable path to our vision.
We’re developing comprehensive data security protocols aligned with best practices in the industry. Our approach includes implementing secure infrastructure, encryption technologies, and protected processing pipelines. As we expand globally, we’re building systems that respect various regional data requirements while still enabling scientific progress. We’re also developing sophisticated federated learning approaches that will allow us to learn from distributed data without compromising privacy or regional data sovereignty requirements. These solutions are evolving alongside our technology to ensure we maintain the highest standards of data protection as we scale.
While DNA remains largely static throughout your life, RNA expression changes dynamically in response to disease, drugs, and environmental factors. RNA serves as a real-time readout of your biological state—what’s actually happening in your cells right now. DNA can tell you about inherited risks, but RNA reveals how those risks are currently manifesting. Additionally, RNA analysis is much more cost-effective than proteomics (analyzing proteins), which can only measure about 10% of proteins at costs around $1 per data point, compared to less than $0.001 per data point with our RNA technology.
Absolutely! We’re actively exploring multiple omics technologies including proteomics, single-cell analysis, methylation profiling, whole genome/exome sequencing, and metabolomics. As we achieve our milestone of reducing costs and enabling data collection at massive scale with RNAseq, we’ll begin introducing these additional technologies to our customer base. These efforts are ongoing, and we welcome discussions about potential collaborations in these areas. Our ultimate goal is to create a multi-omics platform that provides the most comprehensive view of biological systems possible, with the same focus on cost reduction, quality, and integrated AI analysis that we’ve pioneered with RNA sequencing.
Getting started is simple! Contact us through the form on our website, and our team will discuss your specific needs. For research institutions and companies interested in RNA sequencing services, we’ll guide you through sample requirements and provide a customized quote based on your project scope. For those interested in our AI tools, we offer demonstrations of OmicsWeb, Copilot, and QuantaQuill to show how they can accelerate your research. We also actively seek clinical partnerships across various disease areas and are happy to discuss potential collaborations that align with your institution’s focus.
get in touchWe Are Here to Help You Level Up Your Research
Get in Touch – Speak with our experts to tailor solutions to your specific research needs.